References
1. Kishorbhai VT, Malaviya, M. . Overview of an ovarian cancer and its treatment aspects. International Journal of Pharmaceutical and Biological Science Archive. 2021;9(2):24-30.
2. Hamburg MA, Collins FS. The Path to Personalized Medicine. New England Journal of Medicine. 2010;363(4):301-4.
3. Vogenberg FR, Isaacson Barash C, Pursel M. Personalized medicine: part 1: evolution and development into theranostics. P & T : a peer- reviewed journal for formulary management. 2010;35(10):560-76.
4. Mancinelli L, Cronin M, Sadée W. Pharmacogenomics: the promise of personalized medicine. AAPS PharmSci. 2000;2(1):E4-E.
5. Mathur S, Sutton J. Personalized medicine could transform healthcare (Review). Biomed Rep. 2017;7(1):3-5.
6. Javaid M, Haleem A. Industry 4.0 applications in medical field: A brief review. Current Medicine Research and Practice. 2019;9(3):102- 9.
7. Ayers A. Personalized Medicine – Future Impact, Pharma Industry Perspective. J Biomol Tech. 2010;21(3 Suppl):S5-S.
8.Molyneux D, Nantulya V. Public-private partnerships in blindness prevention: Reaching beyond the eye. Eye (London, England). 2005;19:1050-6.
9.Bhatt P, Narvekar P, Lalani R, Chougule MB, Pathak Y, Sutariya V. An in vitro Assessment of Thermo-Reversible Gel Formulation Containing Sunitinib Nanoparticles for Neovascular Age-Related Macular Degeneration. AAPS PharmSciTech. 2019;20(7):281.
10. Uddin M, Wang Y, Woodbury-Smith M. Artificial intelligence for precision medicine in neurodevelopmental disorders. npj Digital Medicine. 2019;2(1):112.
11. Jigar Vyas HP, Himan Patel. . Comparative Study of Etoricoxib Loaded Solid Dispersion and Beta-cyclodextrin Complexes for improvement of Dissolution Profile, Research Journal of Pharmaceutical Dosage Forms and Technology. 2020;12(2):63-7.
12. Mathur S, Sutton J. Personalized medicine could transform healthcare. Biomed Rep. 2017;7(1):3-5.
13.Personalized Medicine Coalition.https://personalizedmedicinecoalition.org/Retrieved Dec 4, 2021.
14. Dudley J, Karczewski K (2014). Exploring Personal Genomics . Oxford: Oxford University Press.
15. Pirmohamed, M. “Pharmacogenetics and pharmacogenomics.”British journal of clinical pharmacology vol. 52,4 (2001): 345-7. doi:10.1046/j.0306-5251.2001.01498.x
16. Xie J, Lee S, Chen X (August 2010). Donev R (ed.). ”Nanoparticle-based theranostic agents”. Advanced Drug Delivery Reviews . Personalized Medicine. Academic Press. 62 (11): 1064–79.
17. Perkovic MN, Erjavec GN, Strac DS, Uzun S, Kozumplik O, Pivac N (March 2017). ”Theranostic Biomarkers for Schizophrenia”. International Journal of Molecular Sciences . 18 (4): 733.
18. Yahata N, Kasai K, Kawato M (April 2017). ”Computational neuroscience approach to biomarkers and treatments for mental disorders”.Psychiatry and Clinical Neurosciences . 71 (4): 215–237
19. ”BIOMARKERTOOLKIT: Companion Diagnostics”https://web.archive.org/web/20140801145112/http://www.amgen.com/pdfs/misc/vpk_biomarker_diagnostics.pdf . Amgen. Archived fromthe original . Retrieved Dec 4, 2021.
20. Pandey S, Giovenzana GB, Szikra D, Baranyai Z (2021). ”Chapter 11. Positron Emission Tomography (PET) Driven Theranostics”. Metal Ions in Bio-Imaging Techniques . Springer. pp. 315–346.
21. Herrmann K, Schwaiger M, Lewis JS, Solomon SB, McNeil BJ, Baumann M, et al. (March 2020). ”Radiotheranostics: a roadmap for future development”. The Lancet. Oncology .21 (3): e146–e156
22. Carney W (2006). ”HER2/neu Status is an Important Biomarker in Guiding Personalized HER2/neu Therapy” (PDF). Connection. 9 : 25–27.
23. Telli ML, Hunt SA, Carlson RW, Guardino AE (August 2007). ”Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility”. Journal of Clinical Oncology. 25(23): 3525–33.
24. Saglio G, Morotti A, Mattioli G, Messa E, Giugliano E, Volpe G, et al. (December 2004). ”Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemia”. Annals of the New York Academy of Sciences. 1028 (1): 423–31.
25. Pleasance E, Titmuss E, Williamson L, et al. (2020). ”Pan-cancer analysis of advanced patient tumours reveals interactions between therapy and genomic landscapes”. Nature Cancer . 1 (4): 452–468.
26. Van Dongen GA, Poot AJ, Vugts DJ. PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2012;33(3):607-15.
27. Malaviya M, Shiroya M. Systemic gene delivery using lipid envelope systems and its potential in overcoming challenges. International Journal of Pharmaceutics and Drug Analysis. 2021;9(1):46-55.
28. Vanpariya F, Shiroya M, Malaviya M. Emulgel: A Review. International Journal of Science and Research (IJSR). 2021;10:847.
29 Bhatt P, Lalani R, Mashru R, Misra A. Abstract 2065: Anti-FSHR antibody Fab’ fragment conjugated immunoliposomes loaded with cyclodextrin-paclitaxel complex for improved in vitro efficacy on ovarian cancer cells. Cancer research. 2016;76(14 Supplement):2065.
30. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, et al. A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation. New England Journal of Medicine. 2011;365(18):1663-72.
31. Narvekar P, Bhatt P, Fnu G, Sutariya V. Axitinib-Loaded Poly(Lactic-Co-Glycolic Acid) Nanoparticles for Age-Related Macular Degeneration: Formulation Development and In Vitro Characterization. ASSAY and Drug Development Technologies. 2019;17(4):167-77.
32. Rose N. Personalized Medicine: Promises, Problems and Perils of a New Paradigm for Healthcare. Procedia - Social and Behavioral Sciences. 2013;77:341-52.
33. Vicente AM, Ballensiefen W, Jönsson J-I. How personalised medicine will transform healthcare by 2030: the ICPerMed vision. Journal of Translational Medicine. 2020;18(1):180.